Clinical bottom line
Patients receiving novel lipid nanoparticle (LNP)-based mRNA therapies may present unique infectious risks related to transient immune modulation and potential nanoparticle-associated effects on host defenses. Current evidence suggests that while these therapies are generally well tolerated, clinicians should maintain vigilance for atypical infections and altered infection presentations, especially in immunocompromised hosts. There is limited direct clinical data on infectious complications specific to LNP-mRNA therapies, warranting cautious interpretation and close monitoring.
What the evidence shows
Lipid nanoparticle-based mRNA delivery platforms have revolutionized therapeutic approaches, enabling targeted protein expression with favorable pharmacokinetics and reduced systemic toxicity. Studies characterizing the physicochemical properties of ionizable lipids used in LNP formulations demonstrate efficient cellular uptake and endosomal escape, critical for mRNA translation [1]. These mechanistic insights underpin the clinical success of mRNA vaccines and emerging mRNA therapeutics.
However, the immunomodulatory effects of LNPs, including transient activation of innate immunity and potential membrane perturbation, may influence host-pathogen interactions. The mRNA-based FRET-FLIM imaging platform revealed that LNPs can induce endosomal membrane damage during cellular entry [3], which could theoretically alter intracellular pathogen handling or immune cell function. While these findings are primarily preclinical, they raise hypotheses about altered susceptibility to infections in treated patients.
Clinical experience with patients receiving mRNA therapies remains limited but parallels can be drawn from cancer patients undergoing novel molecular therapies, who often experience central nervous system infections due to immunosuppression and blood-brain barrier disruption (Pruitt et al., 2017). Although mRNA-LNP therapies differ mechanistically, vigilance for opportunistic or atypical infections is prudent, particularly in patients with underlying immunocompromise or concurrent immunosuppressive treatments.
Additionally, lipid nanoparticle-based mRNA delivery has been explored for therapeutic modulation of tumor microenvironments, such as improving pancreatic ductal adenocarcinoma redox balance by suppressing HTRA1/HIF1 signaling [4]. These applications highlight the expanding clinical contexts in which infectious risk assessment must be integrated.
Caveats and uncertainty
Direct clinical data on infection risk specifically attributable to LNP-mRNA therapies are sparse. Most mechanistic studies derive from in vitro or animal models, limiting extrapolation to human infectious disease outcomes. The transient innate immune activation induced by LNPs may vary by formulation and dose, and its clinical relevance to infection susceptibility remains unquantified.
Furthermore, patient populations receiving mRNA therapies are heterogeneous, often with coexisting conditions or concomitant immunomodulatory treatments confounding infectious risk assessment. The absence of large-scale prospective surveillance or controlled studies focused on infectious complications in this context limits definitive guidance.
Finally, the evolving nature of mRNA therapeutics, including novel lipid chemistries and delivery platforms, necessitates ongoing evaluation as new agents enter clinical use.
How this may change practice
Clinicians should incorporate awareness of potential infectious risks when managing patients receiving LNP-based mRNA therapies, particularly in immunocompromised individuals or those with prior infection history. This includes:
- Maintaining a low threshold for investigating atypical infections or unusual clinical presentations.
- Close monitoring during and after therapy initiation for signs of infection.
- Considering infectious disease consultation for complex cases or unexplained febrile syndromes.
- Integrating infection prevention strategies tailored to the patient’s overall immunologic status.
As clinical experience accumulates, infectious disease specialists will play a critical role in defining best practices for prophylaxis, diagnosis, and management of infections in this emerging therapeutic landscape.